Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (11195)	11/15/1997 7:38:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

<<While emerging resistance of the virus to protease inhibitors and the cocktail is clearly a setback, it was expected by many who were familiar with the exceptional ability of the virus to mutate.>> Andy, The virus' ability to mutate has always been a major problem, especially for those infected with HIV. However, its ability to remain viable in a latent state is a major plus for AGPH's bottom line as is the spread of resistant strains. As far as AGPH's price is concerned, most Biotechs have been hit fairly hard in the past several weeks and many investors are not happy campers. When I began posting about the PI resistance patterns, investors were amazed that AGPH's price could dip to $44 and they were quite pleased when it went back into the 50's. Now they are amazed that it could get down to $40.